Stock Analiz

Rallybio Corp RLYB

Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026

$15.72Market cap $88M
Open the interactive analysis →

Rallybio Corp (RLYB) is a healthcare company listed in the US with a market value of about $88M. In the twelve months to September 30, 2026 it had revenue of $434000 and net income of $27M, a net margin of 6177.4%.

Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is track record (0/5).

Key numbers: a P/E of 3.4, a price to free cash flow of 2.8, a 5-year average ROIC of -59%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 54% below the current price.

About Rallybio

Rallybio is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. It was profitable in 0 of the last 6 years in our data. Its share count rose by 42% over three years (dilution for shareholders). It spends 2284% of revenue on research and development.

Score: 2.0 / 5

Value3/5
Future growth3/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Revenue growth above 10% last year
  • Profit margin improving
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow

Checks not passed

  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • 3-year revenue growth above 10% a year
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row

Valuation

P/E (TTM)3.4
Forward P/E—
P/FCF2.8
P/S202.8
P/B1.0
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield35.2%
Shareholder yield0.0%
Intrinsic value vs. price−54%

Growth and quality

Revenue growth (1 yr)34.9%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-5065.2%
ROIC (5-yr avg.)-58.9%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 6 years

Fiscal yearTTM202520242023202220212020
Revenue$434000$858000$636000————
Net income$27M-$9M-$58M-$75M-$67M-$47M-$26M
Free cash flow$31M—-$49M-$60M-$57M-$46M-$22M
EPS (diluted)$4.56$-1.59$-10.61$-14.72$-16.72$-14.72$-12.16
Net margin6177.4%-1046.4%-9084.1%————
ROIC—-56.9%-97.9%-74.1%-40.0%-25.9%-18.6%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Rallybio’s P/E ratio?

About 3.4, based on the last twelve months of diluted earnings per share.

Is Rallybio stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 54% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Rallybio pay a dividend?

Not currently.

Is Rallybio a good stock to buy?

We do not give buy or sell advice. Rallybio scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.